Le quote di ricavo sono stime per year ended March 31, 2026, non cifre tratte da un documento depositato.
Regular traditional Chinese medicine pieces
Medicinal plants processed into forms such as cut pieces or powders, generally prepared by boiling or decoction before use.
Directly-Oral advanced TCMP
Processed herbal medicines made to be taken by mouth without first being boiled as a decoction.
After-Soaking-Oral advanced TCMP
Small sealed bags of herbal material steeped in hot water to make an infusion.
SanQiFen
A directly swallowed powder made from the roots and rhizomes of notoginseng.
CuYanHuSuo
A directly swallowed powder made from the tubers of Corydalis yanhusuo.
LuXueJing
A directly swallowed product made from dried deer blood.
China SXT makes traditional Chinese medicine pieces (TCMP) from medicinal plants, including herbs prepared as powders and other forms. In the fiscal year ended March 31, 2026, regular TCMP made up 95.02% of revenue (FY2026, high), while advanced TCMP made up 4.35% (FY2026, high); some advanced products can be swallowed directly or steeped in hot water. Total revenue was $1,138,052 (year ended March 31, 2026, high).
Costruito dai documenti depositati da China SXT Pharmaceuticals, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
SXTC · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
2,96 USD+8,4%chiusura 13 nov
Dati fino al 31 marzo 2026, dal 20-F depositato il 1 luglio 2026
China SXT sells Chinese herbal medicines, mainly traditional Chinese medicine pieces, to hospitals and pharmaceutical distributors in China.
The themes China SXT Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade F-
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Mostra 2 trimestri su 15 dello storico dei voti di China SXT Pharmaceuticals, Inc.. Gli altri 13 risalgono fino a agosto 2019.
